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Abstract
Objective: To evaluate the sex differences in cognitive course over 4 years in Parkinson’s disease (PD) patients with
and without mild cognitive impairment (MCI) compared to controls. Methods: Four-year longitudinal cognitive scores
of 257 cognitively intact PD, 167 PD-MCI, and 140 controls from the Parkinson’s Progression Markers Initiative were
included. Longitudinal scores of men and women, and PD with and without MCI were compared. Results: Women had
better verbal memory, men had better visuospatial function. There was no interaction between sex, diagnostic group,
and/or time (4-year follow-up period). Conclusions: Sex differences in cognitive course in de novo PD are similar to
healthy aging. Cognitive decline rates in PD with and without MCI are similar for the first 4 years of PD.
Keywords: Parkinson’s disease, Cognition, Sex, Longitudinal studies, Memory, Decline

INTRODUCTION
Munro et al., 2012). Similar differences have been observed
in PD (Liu et al., 2015). In addition, in PD patients with over 8
years of disease, men show higher risk for dementia and faster
decline once cognitively impaired (Cholerton et al., 2018).
This is in contrast to AD, where women have more rapid
declines once impaired (Burke et al., 2018). Better understanding of sex-based differences in risk for and trajectory
of cognitive decline in newly diagnosed PD patients may help
shape treatment approaches or clinical management of early
cognitive impairments.
In this study, we investigated changes in cognitive scores
over time in men and women newly diagnosed with PD using
the Parkinson’s Progression Markers Initiative (PPMI) database. We evaluated whether men would deteriorate faster
than women, as male sex has been reported as a risk factor
for dementia in PD patients with longer disease duration
(Cholerton et al., 2018). Depression and anxiety impact cognition and brain functioning (Dotson et al., 2014), and excessive daytime sleepiness is a risk factor for cognitive decline in
healthy populations (Jaussent et al., 2012). We assessed
whether deterioration rate was faster and whether the cognitive scores declined more in the PD-MCI compared to cognitively intact PD independent of mood, sleepiness and
motor impairment changes. Finally, as the apolipoprotein E
gene ϵ4 allele (APOE-ϵ4) is a common AD risk factor and

Cognitive impairment is a common non-motor symptom of
Parkinson’s disease (PD). At early stages, up to a third of
PD patients fulfill diagnostic criteria for mild cognitive
impairment (MCI) (Aarsland et al., 2010; Broeders et al.,
2013; Litvan et al., 2011). Within 5 to 6 years, half of cognitively intact PD patients develop MCI, and all patients with
MCI progress to dementia (Broeders et al., 2013; Pigott et al.,
2015). Despite these stark statistics, some longitudinal
studies with de novo PD show progression rates comparable
to healthy controls (HC) (de la Riva, Smith, Xie, &
Weintraub, 2014). This discrepancy may be due to inclusion
of PD patients with varying levels of known risk factors
for cognitive impairment, including increased age, longer
disease duration, male sex, more severe motor symptoms,
non-motor symptoms such as neuropsychiatric disturbances,
genetic factors, and comorbid Alzheimer’s disease (AD)
pathology (Aarsland et al., 2010; G. Liu et al., 2017).
In healthy individuals, sex is associated with different cognitive profiles across the lifespan; women generally perform
better on verbal learning and memory, and men perform
better on visuospatial tasks (Brunet, Caldwell, & Miller, 2018;
*Correspondence and reprint requests to: Ece Bayram, University of
California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0886, USA.
E-mail: drecebayram@gmail.com
1

Downloaded from https://www.cambridge.org/core. University of Nevada - Las Vegas, on 30 Dec 2019 at 20:36:13, subject to the Cambridge Core terms of use, available at
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617719001085

2
is associated with executive dysfunction in PD (Samat, Abdul
Murad, Mohamad, Abdul Razak, & Mohamed Ibrahim,
2017); differences in APOE-ϵ4 frequency across groups were
investigated.

METHOD
Data were downloaded from the PPMI website on May 10,
2018 (http://www.ppmi-info.org/). The PPMI is a multi-site
study collecting data on aspects of PD longitudinally.
Design and aims have been previously published (Marek
et al., 2011) and can be found on their website (http://
www.ppmi-info.org/study-design). The PPMI was approved
by the institutional review boards of all participating sites,
and all participants provided written informed consent.
In our study, patients were separated into two groups: PDnormal cognition (PD-NC) (n = 257) and PD-MCI (n = 167).
MCI was defined by standard scores of ≥1.5 SD below appropriate norms on at least two cognitive tests (Litvan et al.,
2012). The HC (n = 140) consisted of individuals 30 years
or older with no current or active clinically significant neurological disorder, and no first-degree relative with idiopathic
PD; cognitively intact with a Montreal Cognitive Assessment (MoCA) score>26, and standard scores within 1.5
SD of appropriate norms on the cognitive battery.

Cognitive Battery
All available cognitive tests were included. MoCA – a screening measure assessing attention, working memory, executive
function, visuospatial function, language, orientation with the
total score ranging from 0 to 30 – was used to index global
cognition (Nasreddine et al., 2005). Phonemic fluency was
assessed by the MoCA (total number of words beginning
with a specific letter produced within 1 min). Hopkins
Verbal Learning Test-Revised (HVLT-R) is a verbal learning/memory test consisting of a list of 12 words presented
in three repeated learning trials, followed by a minimum
20-min delayed recall and recognition (Benedict, Schretlen,
Groninger, & Brandt, 1998). Benton Judgment of Line
Orientation 15-item (JLO) is a 15-item spatial perception
and orientation measure requiring matching two angled lines
to a set of 11 lines arranged in a semicircle (Benton, Varney,
& Hamsher, 1978). Symbol-Digit Modalities Test (SDMT) is
a processing speed test requiring transposition of symbols for
90 s, following a key (Smith, 1968). Wechsler Memory
Scale-III Letter Number Sequencing (LNS) is a verbal working memory measure, including auditory presentation of
letter and number sequences, requiring recitation of first
the numbers in an ascending order and then the letters in
an alphabetical order (Wechsler, 1997). Animal naming is
a semantic fluency test requiring naming as many animals
as possible in 1 min (Rosen, 1980). Higher scores indicate
better performance for all.
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Other Assessments
The 15-item Geriatric Depression Scale (GDS) is a self-report
scale measuring depressive symptoms (Meara, Mitchelmore,
& Hobson, 1999). State and Trait Anxiety Inventory (STAI)
consists of self-report of state and trait anxiety (Spielberger,
Gorsuch, & Lushene, 1970). Epworth Sleepiness Scale (ESS)
is a self-report scale of sleepiness in daily activities (Johns,
1991). Motor impairment in PD was assessed using
Movement Disorders Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) Part III (Goetz et al., 2008).
Higher scores indicate worse symptoms for all.

Statistical Analysis
Data were analyzed using IBM SPSS version 23 (Armonk,
NY) and SAS (SAS Institute Inc., Cary, NC). Cognitive and
other assessment scores from baseline and annual follow-up
visits (years 1, 2, 3, 4) were analyzed. Demographics and
baseline scores were compared between groups using
Chi-square tests, independent samples t tests and analysis
of variance (ANOVA). Longitudinal changes in other assessments were evaluated using repeated measures ANOVA.
Longitudinal course of cognition was evaluated with repeated
measures analysis of covariance. Years of education and
MDS-UPDRS Part III were not matched, thus included as
covariates. Longitudinal GDS, STAI, ESS were included
as covariates due to previously reported cognitive associations and significant differences between diagnostic groups
and/or sexes in our sample. Sidak correction was used for
multiple comparisons. p < .05 was considered statistically
significant.

RESULTS
Demographics, Clinical Features, and Other
Assessment Scores
Baseline comparisons
Descriptive statistics and comparisons for demographics,
clinical features, other assessment scores at baseline are given
in Table 1. There were no significant diagnostic groups by sex
interaction effects on any of these measures. Women had less
years of education, higher STAI-Trait than men, and showed
a trend toward younger age. APOE-ϵ4 frequency, GDS, ESS,
STAI-State, disease duration, HYS, MDS-UPDRS Part III
were similar between men and women. Regarding diagnosis,
PD-MCI was less educated than HC and PD-NC, though education was similar for HC and PD-NC. HC had lower STAI
than both PD groups, with no STAI difference between PD
groups. PD-MCI had higher MDS-UPDRS Part III than
PD-NC. Age, APOE-ϵ4 frequency, GDS, ESS were similar
across diagnostic groups. Disease duration and HYS did
not differ between PD groups.
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Parkinson’s disease patients with
normal cognition (PD-NC) (n = 257)

Parkinson’s disease patients with
mild cognitive impairment
(PD-MCI) (n = 167)

Women
(n = 100)

Men
(n = 157)

Women
(n = 45)

Healthy controls (HC) (n = 140)

Men (n = 122)

Women
(n = 56)

Men
(n = 84)

Number of participants
with years 1/2/3/4 data
Age

82/71/67/59

136/123/116/111

43/40/38/35

105/97/85/76

56/56/54/52

82/81/78/75

60.03 (9.40)

61.33 (10.45)

62.20 (10.03)

63.15 (8.9)

59.21 (12.33)

61.89 (11.26)

Years of education

15.67 (2.92)

16.05 (2.90)

14.40 (3.32)

15.20 (2.91)

15.77 (2.77)

16.62 (2.98)

19.8

29.7

25.6

27.9

31.2

24.4

7.11 (7.72)

5.89 (6.03)

6.24 (6.39)

6.96 (5.94)

n/a

n/a

5.22 (1.37)

5.18 (1.43)

5.36 (1.24)

5.33 (1.55)

5.30 (1.44)

5.11 (1.57)

33.32 (11.37)

31.75 (10.07)

35.23 (10.18)

33.52 (9.40)

28.54 (8.96)

26.83 (7.06)

Apolipoprotein E-ϵ4
carriers, %
Disease duration, months

15-item Geriatric
Depression Scale
(GDS)
State and Trait Anxiety
Inventory-State

Statistical comparisons
Diagnostic group

Sex

Diagnostic group
and sex interaction

F(2,556) = 1.505,
p = .223, partial
η2 = .005
F(2,556) = 8.655,
p < .001*,
partial η2 = .030
– PD-NC vs. HC:
p = .584
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs. PDNC: p = .003*
χ2(2) = .091,
p = .955, ϕ = .013
F(1,403) = .018,
p = .894, partial
η2 = .000
F(2,556) = .474,
p = .623, partial
η2 = .002
F(2,556) = 17.306,
p < .001*,
partial η2 = .059
– PD-NC vs. HC:
p < .001*
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs.
PD-NC: p = .224

F(1,556) = 3.824,
p = .051, partial
η2 = .007
F(1,556) = 6.614,
p = .010*, partial
η2 = .012

F(2,556) = .305,
p = .737, partial
η2 = .001
F(2,556) = .429,
p = .651, partial
η2 = .002

χ2(1) = .747,
p = .388, ϕ = .038
F(1,403) = .121,
p = .728, partial
η2 = .000
F(1,556) = .455,
p = .500, partial
η2 = .001
F(1,556) = 3.421,
p = .065, partial
η2 = .006

F(1,403) = 1.822,
p = .178, partial
η2 = .005
F(2,556) = .141,
p = .869, partial
η2 = .001
F(2,556) = .003,
p = .997, partial
η2 = .000

Sex differences in PD cognition
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Table 1. Means (SD) and statistical comparisons of baseline measures

(Continued)
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Parkinson’s disease patients with
normal cognition (PD-NC) (n = 257)

Parkinson’s disease patients with
mild cognitive impairment
(PD-MCI) (n = 167)

Women
(n = 100)

Men
(n = 157)

Women
(n = 45)

33.27 (10.23)

31.29 (8.90)

Epworth Sleepiness Scale

5.76 (3.65)

Movement Disorders
Society-Unified
Parkinson’s Disease
Rating Scale Part III
Hoehn and Yahr Stage

Healthy controls (HC) (n = 140)

Men (n = 122)

Women
(n = 56)

Men
(n = 84)

35.91 (10.88)

31.89 (8.65)

30.57 (8.94)

27.87 (5.78)

5.89 (3.56)

4.98 (3.45)

5.94 (3.17)

5.38 (3.17)

5.78 (3.48)

19.24 (8.48)

19.58 (8.59)

23.58 (8.85)

22.73 (10.10)

n/a

n/a

1.55 (.50)

1.53 (.51)

1.58 (.54)

1.63 (.48)

n/a

n/a

Montreal Cognitive
Assessment

28.38 (1.30)

28.06 (1.35)

25.61 (2.58)

25.44 (2.55)

28.43 (1.06)

28.21 (1.12)

Phonemic fluency

13.76 (4.06)

13.32 (5.05)

12.07 (4.46)

12.43 (4.55)

14.48 (3.63)

14.65 (4.87)

State and Trait Anxiety
Inventory-Trait

Statistical comparisons
Diagnostic group

Sex

Diagnostic group
and sex interaction

F(2,556) = 9.554, F(1,556) = 12.423,
p < .001*,
p < .001*,
partial η2 = .033
partial η2 = .022
– PD-NC vs. HC:
p = .004*
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs.
PD-NC: p = .258
F(1,556) = 2.484,
F(2,556) = .539,
p = .116, partial
p = .583, partial
η2 = .004
η2 = .002
F(1,420) = 13.854,
F(1,420) = .192,
p < .001*,
p = .662, partial
η2 = .000
partial η2 = .032

F(2,556) = .622,
p = .537, partial
η2 = .002
F(1,420) = .049,
p = .825, partial
η2 = .000

F(1,420) = .086,
p = .770, partial
η2 = .000
F(1,548) = 1.981,
p = .160, partial
η2 = .004

F(1,420) = .467,
p = .495, partial
η2 = .001
F(2,548) = .059,
p = .943, partial
η2 = .000

F(1,548) = .282,
p = .596, partial
η2 = .001

F(2,548) = .250,
p = .779, partial
η2 = .001

F(1,420) = 1.420,
p = .234, partial
η2 = .003
F(2,548) = 95.094,
p < .001*,
partial η2 = .258
– PD-NC vs. HC:
p = 1.000
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs.
PD-NC: p <
.001*
F(2,548) = 5.126,
p = .006*, partial
η2 = .018
– PD-NC vs. HC:
p = .084
– PD-MCI vs. HC:
p = .005*
– PD-MCI vs.
PD-NC: p = .114

F(2,556) = .556,
p = .574, partial
η2 = .002
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Table 1. (Continued )

(Continued)

Parkinson’s disease patients with
normal cognition (PD-NC) (n = 257)

Parkinson’s disease patients with
mild cognitive impairment
(PD-MCI) (n = 167)

Women
(n = 100)

Men
(n = 157)

Women
(n = 45)

Hopkins Verbal Learning
Test-Revised-Learning

27.74 (3.55)

25.69 (4.18)

Hopkins Verbal Learning
Test-Revised-Delayed
recall

9.80 (1.77)

Benton Judgment of Line
Orientation
15-item

Healthy controls (HC) (n = 140)

Men (n = 122)

Women
(n = 56)

Men
(n = 84)

22.64 (4.98)

20.83 (4.37)

28.14 (3.99)

26.41 (3.92)

9.03 (2.10)

7.66 (2.50)

6.57 (2.42)

10.27 (1.66)

9.48 (2.29)

12.33 (2.03)

13.57 (1.63)

11.59 (2.40)

12.59 (2.30)

12.41 (2.24)

13.75 (1.64)

Symbol Digit Modalities
Test

43.69 (9.34)

40.75 (9.46)

40.70 (9.18)

41.80 (10.75)

45.20 (9.68)

45.49 (12.56)

Wechsler Memory ScaleIII Letter Number
Sequencing
Animal naming

10.86 (2.61)

10.60 (2.72)

10.14 (2.14)

10.79 (2.66)

10.73 (2.28)

11.07 (2.82)

21.73 (5.58)

21.39 (5.35)

20.82 (5.35)

20.83 (5.23)

22.20 (5.65)

21.56 (5.59)

Statistical comparisons
Diagnostic group

Sex

F(2,548) = 51.064, F(1,548) = 26.627,
p < .001*,
p < .001*,
partial η2 = .157
partial η2 = .046
– PD-NC vs. HC:
p = .975
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs. PDNC: p < .001*
F(2,548) = 41.167, F(1,548) = 23.344,
p < .001*,
p < .001*,
partial η2 = .131
partial η2 = .041
– PD-NC vs. HC:
p = .913
– PD-MCI vs. HC:
p < .001*
– PD-MCI vs. PDNC: p < .001*
F(2,548) = 4.834, F(1,548) = 36.480,
p = .008*, partial
p < .001*,
2
η = .017
partial η2 = .062
– PD-NC vs. HC:
p = .195
– PD-MCI vs. HC:
p = .996
– PD-MCI vs. PDNC: p = .020*
F(1,548) = .322,
F(2,548) = 2.340,
p = .571, partial
p = .097, partial
η2 = .001
η2 = .008
F(2,548) = 1.119,
F(1,548) = 1.157,
p = .327, partial
p = .283, partial
η2 = .004
η2 = .002
F(2,548) = 1.015,
F(1,548) = .032,
p = .363, partial
p = .859, partial
η2 = .004
η2 = .000

Diagnostic group
and sex interaction
F(2,548) = .022,
p = .978, partial
η2 = .000

Sex differences in PD cognition
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Table 1. (Continued )

F(2,548) = .341,
p = .711, partial
η2 = .001

F(2,548) = .240,
p = .787, partial
η2 = .001

F(2,548) = 2.150,
p = .117, partial
η2 = .008
F(2,548) = 1.635,
p = .196, partial
η2 = .006
F(2,548) = .210,
p = .811, partial
η2 = .001

Variables are reported as mean (SD) or percentage. PD-NC, Parkinson’s disease patients with normal cognition; PD-MCI, Parkinson’s disease patients with mild cognitive impairment; HC, healthy controls; n/a, not
applicable.
*
Statistical significance.
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Fig. 1. Changes in cognitive scores over time.

Longitudinal comparisons
Results are presented in Supplementary Table 1. GDS, STAI,
MDS-UPDRS Part III did not change over time, while ESS
increased over time. Men had higher ESS, lower STAITrait compared to women, though GDS and STAI-State were
similar across sexes. Both PD groups had higher STAI and
ESS than HC. PD-MCI showed a trend toward higher
GDS compared to HC, but GDS was not different between
PD-NC and HC. The only significant difference between
PD-NC and PD-MCI was MDS-UPDRS Part III, with higher
scores for the PD-MCI. The only diagnostic group and sex
interaction effect was for MDS-UPDRS Part III, with difference between the PD-NC and PD-MCI more pronounced
in women.

Cognition
Baseline comparisons
Descriptive statistics and comparisons at baseline are shown
in Table 1. Women scored higher on HVLT-R learning and
delayed recall,and lower on JLO. MoCA, phonemic fluency,

SDMT, LNS, animal naming were similar between men and
women. Regarding diagnosis, SDMT, LNS, animal naming
were similar across the diagnostic groups, and all cognitive
scores were similar between PD-NC and HC. PD-MCI scored
lower than HC on MoCA, phonemic fluency, HVLT-R learning, and delayed recall. JLO was similar between PD-MCI
and HC. PD-MCI scored lower than PD-NC on MoCA,
HVLT-R learning and delayed recall, and JLO, but showed
similar scores as PD-NC on phonemic fluency. There were
no significant diagnostic groups by sex interactions.

Longitudinal comparisons
The change in cognition over time is demonstrated in Figure 1
(Supplementary Tables 2–3 for results).
MoCA, HVLT-R learning and delayed recall, animal naming did not change over time. Phonemic fluency increased,
SDMT and LNS decreased, and JLO showed a trend toward
decreasing. There were no significant three- or two-way interactions of diagnostic group, sex, or time. Women scored
higher on MoCA, HVLT-R learning and delayed recall and
lower on JLO. Phonemic fluency, SDMT, LNS, animal
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Sex differences in PD cognition
naming were similar between men and women. Regarding
diagnosis, LNS and animal naming were similar across diagnostic groups. PD-NC scored lower than HC on SDMT, but
similarly to HC across all other measures. PD-MCI scored
lower than HC on MoCA, phonemic fluency, HVLT-R learning and delayed recall, JLO, SDMT, and lower than PD-NC
on MoCA, phonemic fluency, HVLT-R learning and delayed
recall, JLO.

Longitudinal covariate effects
There were several significant covariate effects on cognition
(Supplementary Table 3). Years of education had a positive
effect on phonemic fluency, HVLT-R learning and delayed
recall, JLO, but a negative effect on animal naming.
Longitudinal GDS had a negative effect on SDMT.
Longitudinal STAI-State had a negative effect on LNS and
animal naming. Longitudinal STAI-Trait did not have a
significant effect on any cognitive measures. Longitudinal
ESS had a negative effect on MoCA, LNS, animal naming.
Longitudinal MDS-UPDRS Part III had a negative effect
on MoCA, HVLT-R learning and delayed recall, JLO, animal
naming.

DISCUSSION
We investigated how cognition changes over time in men and
women with de novo PD, with and without MCI. Women
performed better on verbal learning and memory, whereas
men had better visuospatial functioning. Controls performed
better than PD-MCI on general cognitive abilities, verbal
learning and memory, visuospatial functioning, and processing speed measures. The PD-NC performed better than
PD-MCI on general cognitive abilities, verbal learning and
memory, and visuospatial functioning, but had reduced
processing speed compared to HC. Across groups, visuospatial function, processing speed, and working memory deteriorated over time. Diagnostic group, sex, and time effects on
cognition were independent, and no interactions between
these factors were found.
Male sex has been associated with more cognitive impairment in PD (Cholerton et al., 2018; but, c.f., Rana, Yousuf,
Naz, & Qa’aty, 2012). Our findings revealed that over 4
years, differences between women and men were confined
to verbal memory and visuospatial functioning, independent
of MCI diagnosis. This cognitive pattern has been previously
reported in healthy aging (Munro et al., 2012), and de novo
PD with cross-sectional, baseline measures of the same PPMI
PD patient sample (R. Liu et al., 2015). In healthy individuals,
sex differences in verbal memory have been suggested to be
due to different cognitive strategies employed, and to
differences in brain language networks between women
and men (Andreano & Cahill, 2009). Our findings indicate
that sex effects on cognition in de novo PD are similar to
those found in healthy aging.
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We did not find any sex differences in trajectory of scores
over time, contrary to reports associating the male sex with a
faster cognitive decline in PD (Cholerton et al., 2018).
However, this faster rate was reported in patients with over
8 years of PD duration, and our sample consisted of only
de novo patients followed for 4 years. As both age and disease
progression are important for PD dementia development
(Levy et al., 2002; Rana et al., 2012), effects of sex on
cognitive decline rate may become more meaningful later
in disease. Other methods, including functional and structural
neuroimaging, may help show subtler sex differences that
may not yet be reflected with cognitive scores. It is also
noteworthy that comorbidities and risk factors which may
impact cognition in PD (Doiron, Langlois, Dupré, &
Simard, 2018) were not evaluated in this study. Future studies
are required to clarify whether comorbidities influence the
effects of sex in PD.
In our sample, clinical course of cognition over 4 years
was similar in PD-NC, PD-MCI, and HC. Previous studies
have reported faster progression to dementia in PD with baseline MCI (Pigott et al., 2015), even in de novo PD (Broeders
et al., 2013). Given the age effects on dementia development,
the discrepancy between these findings and those of Broeders
and colleagues (Broeders et al., 2013) may be due to our sample being younger. Although we cannot test this hypothesis, it
is also possible that our PD-MCI group is less impaired at
baseline, which would explain differences in longitudinal trajectory. The use of alternate HVLT-R, SDMT, and JLO forms
for each year, despite mitigating practice effects, may also
have contributed to our lack of finding by adding noise to
the data. In addition, our measure of decline differs in important ways as we captured the decline in raw scores instead of
assessing the percentage of patients with cognitive decline.
Finally, the decrease in our sample size over time is significant, and our negative result may be due to a bias toward
better-functioning individuals remaining in the study.
The increase in phonemic fluency scores over time is
somewhat surprising given the deteriorating effects of aging
on cognition (Harada, Natelson Love, & Triebel, 2013). This
enhanced performance may be due to practice effects, given
the repeated use of the same MoCA form, despite use of alternate forms of other measures (i.e., HVLT-R, SDMT, and
JLO). This would be consistent with a study showing that
phonemic fluency was the only test of 25 measures showing
increased scores due to practice effects over a period of 1 year
in healthy aging (Bartels, Wegrzyn, Wiedl, Ackermann, &
Ehrenreich, 2010).
We included longitudinal mood, sleepiness, and motor
impairment scores as covariates and found group and/or
sex effects in these variables. In healthy elderly, depression
was associated with processing speed, working memory,
and executive functions deficits, whereas anxiety was associated with better attention and working memory (Dotson et al.,
2014). Our results suggest that depression is associated with
reduced processing speed, while state anxiety is associated
with reduced working memory and linguistic skills. The
opposite relationship of anxiety with cognition in healthy
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adults and our sample (with the majority consisting of PD
patients) can be investigated further to establish effects of
anxiety on cognition in PD. Worse daytime sleepiness scores
were associated with lower scores on MoCA, reduced working memory, and linguistic skills. This is in line with a previous study reporting that excessive sleepiness can predict
cognitive decline determined by the Mini Mental State
Examination, a brief global cognitive scale (Jaussent et al.,
2012). As the motor impairment (MDS-UPDRS Part III) progressed over time, MoCA, verbal learning and memory,
visuospatial functioning and language deteriorated. This is
not surprising as cognitive decline increases over time as the
disease progresses and worse motor impairment at baseline
may predict future cognitive decline (Broeders et al., 2013;
Pigott et al., 2015). However, more direct testing of these variables was beyond the scope of the article and deserves future
studies. In addition, the frequency of APOE-e4 carriers was
similar across the groups and the sexes, and thus the association was not evaluated further. Future studies could investigate a potential mediating effect of APOE-ϵ4 on cognitive
decline in men and women with PD.
In conclusion, sex had similar cognitive effects in de novo
PD as healthy individuals, and decline over 4 years did not
differ between men and women with de novo PD or between
PD-NC and PD-MCI. In early PD, in contrast to findings for
AD, sex does not appear to affect cognition differently. We
acknowledge that the PPMI includes limited cognitive assessment, and more extensive cognitive batteries may be helpful
in further fleshing out sex differences. Use of such batteries
would also allow classification of PD-MCI and provide more
reliable results as PD-MCI is rather heterogeneous. Future
investigations including longitudinal neuroimaging may
further elucidate the course of pathophysiology in women
and men with PD, as well as PD-NC and PD-MCI.
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